The National Community Pharmacists Association, the National Association of Chain Drug Stores, and the National Association of Specialty Pharmacy issued a statement regarding the Centers for Medicare & Medicaid Services’ release on Monday of the proposed rule titled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses."
The legislation will prevent restrictions on pharmacists’ ability to tell patients when they can save money on prescriptions by paying cash instead of using insurance. Meanwhile, NACDS positions DIR fee reform as another crucial issue for lowering out-of-pocket drug costs.
The Patient Right to Know Drug Prices Act (S. 2554) is part of the effort to empower pharmacists to help patients lower out-of-pocket drug costs.
The bills would make it easier for Medicare patients to save money on prescription drugs.
NACDS has submitted comments to Health and Human Services Secretary Alex Azar in response to the agency’s request-for-information on drug-pricing public policy issues.
NACDS RxIMPACT pharmacy advocates are urging Senators to sign a letter to U.S. Secretary of Health and Human Services Secretary Alex Azar that is being led by Sen. Shelley Moore Capito (R-WV) and Sen. Jon Tester (D-MT).
CMS signals potential action on DIR fee reform, takes action on NACDS-backed strategy to help address opioid abuse epidemic.
NACDS expressed support for, and provided further input, on CMS’ proposed rule, which involves issues including direct and indirect remuneration fees; e-prescribing; medication therapy management; opioid abuse; and fostering pharmacy access.
E-prescribing, opioid issues, medication therapy management, pharmacy access addressed by Centers for Medicare & Medicaid Services.
NACDS print ads, and Coalition radio and digital ads, are running in selected Congressional Districts this August to tout the Pharmacy and Medically Underserved Areas Enhancement Act.